Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioPharma CreditLSE:BPCR -0.41%52 Graham Number is $1.62 as of Dec. 2025, which is 145% above its 10-year median of 0.66. GuruFocus rates LSE:BPCR with a GF Score™ of 52/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,170 Asset Management companies, BioPharma Credit ranks better than 62.56% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-20), the stock price of BioPharma Credit is $0.96. BioPharma Credit's graham number for the quarter that ended in Dec. 2025 was $1.62. Therefore, BioPharma Credit's Price to Graham Number ratio for today is 0.59.
The historical rank and industry rank for BioPharma Credit's Graham Number or its related term are showing as below:
LSE:BPCR'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.54 Med: 0.66 Max: 0.84
Current: 0.59
During the past 9 years, the highest Price to Graham Number ratio of BioPharma Credit was 0.84. The lowest was 0.54. And the median was 0.66.
LSE:BPCR's Price-to-Graham-Number is ranked better than 62.56% of 1170
companies
in the Asset Management industry
Industry Median: 0.71
vs LSE:BPCR: 0.59
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
BioPharma Credit (LSE:BPCR) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
BioPharma Credit's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Dec. 2025 )
=
0.96
/
1.62
=
0.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
BioPharma Credit Graham Number Related Terms
BioPharma Credit Graham Number Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:BPCR vs BLK, BX, KKR: Graham Number Comparison
For the Asset Management subindustry, BioPharma Credit's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit Price-to-Graham-Number vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a Graham Number of $1.62 as of Dec. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on BioPharma Credit and its competitors. This is 145% above median its historical median of 0.66. Over the past decade, BioPharma Credit's Graham Number has ranged from 0.54 to 0.84. According to the industry distribution chart, BioPharma Credit ranks #438 out of 1170 companies in the Asset Management industry, placing it in the top 37.4%.
Is BioPharma Credit's Graham Number too high?
BioPharma Credit's current Graham Number of $1.62 is 145% above median its 10-year median of 0.66. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 0.84. The Asset Management industry median Graham Number is 0.71. BioPharma Credit's value of $1.62 is 128.2% above this industry median. Based on the distribution chart, BioPharma Credit ranks #438 out of 1170 companies in the Asset Management industry, which is above the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's Graham Number compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #438 out of 1170 companies for Graham Number. This puts BioPharma Credit in the upper half of its industry. The industry median Graham Number is 0.71. BioPharma Credit's value of $1.62 is 128.2% above this benchmark. Historically, BioPharma Credit's own Graham Number has ranged from 0.54 to 0.84 over the past decade. While the company's 10-year median is 0.66 vs. the industry median of 0.71, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for an Asset Management company?
The median Graham Number among Asset Management companies is 0.71, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current Graham Number of $1.62 is 128.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on BioPharma Credit and its competitors. For the Asset Management industry, the median Graham Number is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current Graham Number is $1.62, which is 145% above median its own 10-year median of 0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading right at its estimated fair value. The current Graham Number is $1.62, which is 145% above median its 10-year median of 0.66 and 128.2% above the Asset Management industry median of 0.71. BioPharma Credit's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current Graham Number is $1.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued.
The current stock price of $0.96 is trading 0% below its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
Graham Number: $1.62 (145% above median its 10-year median of 0.66)
GF Value™: $0.96 vs. price of $0.96 (0% below fair value)
Industry Position: 128.2% above the Asset Management median (#438 of 1170)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
52GF Score
Get the complete analysis for LSE:BPCR
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
